Standard dosing regimen of liposomal amphotericin B is as effective as high-loading dose for patients with invasive aspergillosis: AmBiLoad trial

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 929-932

  Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

AmBiLoad trial; Invasive aspergillosis; L AMB; Polyene; Primary antifungal therapy

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; HOST; HUMAN; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MORBIDITY; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; SURVIVAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HEMATOLOGIC NEOPLASMS; HUMANS; HYPOKALEMIA; NEPHROTIC SYNDROME; NEUTROPENIA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 37349065139     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.929     Document Type: Article

References (19)

1. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infec. Dis. 44, 1289-1297 (2007).
2. Denning DW. Invasive aspergillosis. Clin. Infect. Dis. 26, 781-805 (1998).
3. Pfaller M, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 34, 7408-7415 (2002).
5. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36, 630-670 (2003).
6. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39, 1563-1571 (2004).
7. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. 340, 764-771 (1999).
8. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin. Infect. Dis. 31, 1155-1163 (2000).
9. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45, 3487-3496 (2001).
10. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol. 103, 205-212 (1998).
11. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 27, 1406-1412 (1998).
12. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob. Agents Chemother. 45, 922-926 (2001).
13. Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28(Suppl B.), 73-82 (1991).
14. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch. Intern. Med. 155, 1093-1098 (1995).
15. Tollemar J, Andersson S, Ringdén O, Tydén G. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 35, 215-220 (1992).
16. Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericn B: clinical experience and perspectives. Expert Rev. Anti Infect. Ther. 3, 167-180 (2005).
17. Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med. Mycol. 44, S315-S318 (2006).
18. Annaissie EJ. Trial design for mold-active agents: time to break the mold - aspergillosis in neutropenic adults. Clin. Infect. Dis. 44, 1298-1306 (2007).
19. De Pauw BE, Patterson TE. Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clin. Infect. Dis. 41(Suppl. 6), S377-S380 (2005).